Inventor · disambiguated record
Felix Bachmann
Also filed as: BACHMANN FELIX
18 granted patents·7 pending applications·31 citations·filing 1997–2022
91Inventor score
Files withBASILEA PHARMACEUTICA AG9LANE HEIDI ALEXANDRA5BASILEA PHARM INT AG4EBERLE MARTIN2SILLAJEN INC2
Top patents by PatentIndex Score
25 records- 0181US9970938B2Use of BUBR1 as a biomarker of drug response to furazanobenzimidazolesBASILEA PHARMACEUTICA AG·Filed 2016·Granted May 15, 2018·2 cites·60 claims
- 0280US8802858B2Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseasesPOHLMANN JENS·Filed 2010·Granted Aug 12, 2014·7 cites·20 claims
- 0377US10067120B2Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazolesBASILEA PHARMACEUTICA AG·Filed 2016·Granted Sep 4, 2018·2 cites·59 claims
- 0477US10006078B2Use of phospho-Akt as a biomarker of drug responseLANE HEIDI ALEXANDRA·Filed 2012·Granted Jun 26, 2018·2 cites·81 claims
- 0574US9995754B2Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazolesLANE HEIDI ALEXANDRA·Filed 2012·Granted Jun 12, 2018·2 cites·28 claims
- 0673US9366682B2Use of stathmin as a biomarker of drug response to furazanobenzimidazolesLANE HEIDI ALEXANDRA·Filed 2012·Granted Jun 14, 2016·3 cites·97 claims
- 0772US9476889B2Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazolesLANE HEIDI ALEXANDRA·Filed 2012·Granted Oct 25, 2016·2 cites·78 claims
- 0870US7423157B2Substituted benzimidazoles and their use for inducing apoptosisBASILEA PHARMACEUTICA AG·Filed 2006·Granted Sep 9, 2008·1 cites·6 claims
- 0967USRE42890EFurazanobenzimidazolesBASILEA PHARMACEUTICA AG·Filed 2004·Granted Nov 1, 2011·4 cites·39 claims
- 1065US8486996B2Aroylfuranes and aroylthiophenesEBERLE MARTIN·Filed 2006·Granted Jul 16, 2013·1 cites·27 claims
- 1165US7385061B2FurazanobenzimidazolesBASILEA PHARMACEUTICA AG·Filed 2004·Granted Jun 10, 2008·3 cites·17 claims
- 1261US10724072B2Use of phospho-Akt as a biomarker of drug responseBASILEA PHARMACEUTICA AG·Filed 2018·Granted Jul 28, 2020·0 cites·65 claims
- 1361US10656162B2Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazolesBASILEA PHARMACEUTICA AG·Filed 2018·Granted May 19, 2020·0 cites·48 claims
- 1459US7951957B2Substituted benzimidazoles and their use for inducing apoptosisBASILEA PHARMACEUTICA AG·Filed 2008·Granted May 31, 2011·0 cites·25 claims
- 1555US2025057844A1Methods of treating neoplastic diseasesSILLAJEN INC·Filed 2022·Application pending·0 cites
- 1651US2025049801A1Pharmaceutical combinations for use in the treatment of neoplastic diseasesSILLAJEN INC·Filed 2022·Application pending·0 cites
- 1751US2022370418A1Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseasesBASILEA PHARM INT AG·Filed 2020·Application pending·0 cites
- 1850US2007167505A1Substituted benzimidazoles and their use for inducing apoptosisBASILEA PHARMACEUTICA AG·Filed 2005·Application pending·0 cites
- 1944US10222377B2Use of BUBR1 as a biomarker of drug response to furazanobenzimidazolesLANE HEIDI ALEXANDRA·Filed 2012·Granted Mar 5, 2019·0 cites·61 claims
- 2038US2022031670A1Pharmaceutical combinations for use in the treatment of neoplastic diseasesBASILEA PHARM INT AG·Filed 2019·Application pending·0 cites
- 2137US11419856B2Pharmaceutical combinations for use in the treatment of neoplastic diseasesBASILEA PHARM INT AG·Filed 2018·Granted Aug 23, 2022·0 cites·32 claims
- 2237US2005130237A1High throughput screening method for compounds with non-, pro-, or anti-apoptotic or proliferative or necrotic activityFiled 2002·Application pending·0 cites
- 2336US8288421B2PhenylaminopyridinesEBERLE MARTIN·Filed 2005·Granted Oct 16, 2012·0 cites·21 claims
- 2433US2018306790A1Use of eb1 as a biomarker of drug responseBASILEA PHARM INT AG·Filed 2016·Application pending·0 cites
- 2528US6713305B1Metastasis-associated antigen and antibodies theretoNOVARTIS AG·Filed 1997·Granted Mar 30, 2004·2 cites·3 claims
Join the waitlist — get patent alerts
Get an alert when Felix Bachmann files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →